williamÍþÁ®ÑÇÖÞ¹Ù·½

EN
EN
  • ÓªÒµ×Éѯ

    Öйú£º

    Email: marketing@medicilon.com.cn

    ÓªÒµ×ÉѯרÏߣº400-780-8018

    £¨½öÏÞ·þÎñ×Éѯ £¬ÆäËûÊÂÒËÇ벦´ò´¨É³×ܲ¿µç»°£©

    ´¨É³×ܲ¿µç»°: +86 (21) 5859-1500

    ÍâÑó£º

    +1(781)535-1428(U.S.)

    0044 7790 816 954 (Europe)

    Email:marketing@medicilon.com

ÔÚÏßÁôÑÔ¡Á
µã»÷Çл»
News information
ÐÂÎÅ×ÊѶ

°ÐÏòÂÑ°×½µ½âϵÁУ¨Èý£©£º·Ö×Ó½º £¬ÌôÕ½²»¿É³ÉÒ©

2023-07-05
|
»á¼ûÁ¿£º

°ÐÏòÂÑ°×Öʽµ½â£¨targeted protein degradation £¬TPD£©ÊÇÒ»ÖÖ¿ìËÙÉú³¤µÄÒ©Îï·¢Ã÷Õ½ÂÔ £¬Ê¹ÓÃС·Ö×ÓÕÐļE3·ºËØÅþÁ¬Ã¸²¢Ôö½øÂÑ°×Ë®½â ¡£ÔÚÖÎÁÆÖ×Áö¡¢Ñ¬È¾²¡¡¢Ñ×Ö¢¼°Éñ¾­ÍËÐÐÐÔ¼²²¡µÈÁìÓò¾ßÓÐÖØ´óµÄDZÁ¦ £¬Í»ÆÆ¡°²»¿É³ÉÒ©¡±ÎÊÌâ ¡£Ëæ×Å·Ö×Ó½º½µ½â¼ÁµÄÐËÆ𠣬·Ö×Ó½º½µ½â¼Á¿ÉÓÕµ¼»òÎȹ̷ºËØÅþÁ¬Ã¸ºÍÄ¿µÄÂÑ°×£¨µ×Î֮¼äµÄÂÑ°×-ÂÑ°×Ï໥×÷Óã¨PPI£©,µ¼ÖÂÂÑ°×ÖÊ·ºËØ»¯ºÍËæºóµÄÂÑ°×øÌå½µ½â ¡£ÏÖÔÚ¶à¼ÒÒ©ÆóÔڽṹ´ËÁìÓò £¬ÓÃÓÚ¿ª·¢ÐµÄÁÆ·¨À´Öª×ãδ֪×ãµÄÁÙ´²ÐèÇó ¡£

1-°ÐÏòÂÑ°×½µ½â¼ÁµÄÉú³¤Àú³Ì.jpg

°ÐÏòÂÑ°×½µ½â¼ÁµÄÉú³¤Àú³Ì[1]

·Ö×Ó½º¸ÅÊö

·Ö×Ó½º½µ½â¼ÁÊÇÒ»Àà¿ÉÓÕµ¼E3·ºËØÅþÁ¬Ã¸µ×ÎïÊÜÌåÓë°ÐÂÑ°×Ö®¼ä±¬·¢Ï໥×÷Óà £¬¾­·ºËØ»¯±»ÂÑ°×øÌå½µ½âµÄС·Ö×Ó ¡£·Ö×Ó½º¿ÉÒÔÔöÇ¿ºÍÎȹÌÂÑ°×ÖÊÏ໥×÷Óà £»»¹ÄÜÐÞ¸´ÒòÍ»±ä¶øÏ÷ÈõµÄÂÑ°×ÖÊÏ໥×÷Óà £»ÇÒÓÕµ¼ E3 ·ºËØÅþÁ¬Ã¸ÓëÂÑ°×ÖʰбêµÄÏ໥×÷Óà £¬½ø¶ø´¥·¢ÁË°ÐÂѰ׵Ķà¾Û·ºËØ»¯ £¬Í¨¹ýÂÑ°×øÌå½µ½â £»·Ö×Ó½º»¹¿ÉÒÔµ÷ÀíÂÑ°×Öʹ¦Ð§ £¬ÀýÈçPKM2 ÊÇÒ»ÖÖÓë°©Ö¢Ïà¹ØµÄ±ûͪËἤø £¬ÔÚͬ¶þ¾ÛÌåÐÎʽÖлîÐÔ½ÏµÍ £¬·Ö×Ó½º¿ÉÒÔÎȹ̶þ¾ÛÌå²¢½«Á½¸ö¶þ¾ÛÌå¡°Õ³ºÏ¡±ÔÚÒ»ÆðÐÎ³É PKM2 ͬËľÛÌå £¬´Ó¶øÔöÌíø»îÐÔ ¡£

2-·Ö×Ó½ººÍ·Ö×Ó½º½µ½â¼Á¼°Æä×÷ÓûúÖÆ.jpg

·Ö×Ó½ººÍ·Ö×Ó½º½µ½â¼Á¼°Æä×÷ÓûúÖÆ[2]

·Ö×Ó½º VS PROTAC

PROTACºÍ·Ö×Ó½º¶¼ÊÇ»ùÓÚ·ºËØÂÑ°×øϵһÇеİÐÏòÂÑ°×Öʽµ½âÊÖÒÕ ¡£ÆäÖÐ £¬PROTACÊÇͨ¹ýÕÐļE3·ºËØÅþÁ¬Ã¸ £¬ÓÕµ¼°ÐÂѰ׿¿½üE3·ºËØÅþÁ¬Ã¸ £¬µ¼Ö°ÐÂÑ°×·ºËØ»¯ºÍ½µ½â ¡£¶ø·Ö×Ó½ºÊÇͨ¹ýÐÞÊηºËØÅþÁ¬Ã¸Íâò £¬Ôö½ø»òÓÕµ¼E3·ºËØÅþÁ¬Ã¸Óë°ÐÂÑ°×Ö®¼ä±¬·¢ÂÑ°×-ÂÑ°×Ï໥×÷Óã¨PPI£© £¬Ê¹°ÐÂÑ°×·ºËØ»¯½ø¶ø½µ½â ¡£

ÓëPROTAC²î±ðµÄÊÇ £¬·Ö×Ó½º¶ÔE3·ºËØÅþÁ¬Ã¸ºÍ°ÐÂÑ°×¾ßÓÐË«ÅäÌå½á¹¹ÌØÕ÷ £¬¼æ¾ßͬÁ½¸öÂÑ°×ÍŽáµÄ¹¦Ð§ £¬Ôö½øÁ½¸öµ°º×±¬·¢·ºËØ»¯, ¶ÔÄÇЩ·Ç¿ÉÒ©Ð԰бêÒÔ¼°ÂÑ°×-ÂÑ°×Ï໥×÷ÓÃÒ²¿ÉÒòÖ®¶ø½µ½â ¡£·Ö×Ó½º»¯Ñ§½á¹¹¼òÆÓ¡¢·Ö×ÓÁ¿Ð¡ £¬Ï¸°ûͨ͸ÐÔ¸ß £¬¿Ú·þÎüÊսϺà £¬ÇÐÊÊÓÃÒ©ÎåÔ­Ôò £¬¾ßÓнϺõijÉÒ©ÐÔ ¡£·Ö×Ó½ºÕ½ÂÔΪ°ÐÏòÂÑ°×½µ½âÁìÓòµÄÒ©Î↑·¢ÌṩÁËеÄÑо¿Ë¼Ð÷ ¡£

3-ͨ¹ý·ºËØ-(Ub)-ÂÑ°×øϵһÇнµ½âÄ¿µÄÂÑ°×-(POI)-ʾÒâͼ£º·Ö×Ó½º(A)£»PROTAC-(B).jpg

ͨ¹ý·ºËØ (Ub)-ÂÑ°×øϵһÇнµ½âÄ¿µÄÂÑ°× (POI) ʾÒâͼ£º·Ö×Ó½º(A) £»PROTAC (B) [1]

·Ö×Ó½º¾ÙÀý

? Cyclosporine A £¨»·æß¾úËØ A£©

»·æß¾úËØ×î³õÊÇÔÚ¿¹ÉúËØɸÖÐÊèÉ¢»ñµÃµÄ ¡ £»·æß¾úËØ A (CsA)ÊÇÒ»Öָ߶ÈÌØÒìÐ﵀ T ϸ°û»î»¯ÒÖÖƼÁ ¡£1984 Äê»·æß¾úËØ A (CsA) ÃâÒßÒÖÖƵÄÉú»¯»úÖÆÊ״α»Õ¹ÏÖ ¡ £»·æß¾úËØ A [Cyclosporin A, CsA] ¿ÉÍŽáÇ×»·ÂÑ°× 18 (Cyp18)ÐγÉCyp18-CsA ¸´ºÏÎï £¬Cyp18/CsA ¸´ºÏÎï¿ÉÒÔÓë¸Æ/¸Æµ÷ÂÑ°×ÒÀÀµÐÔË¿°±Ëá-ËÕ°±ËáÂÑ°×Á×Ëáø¸Æµ÷Éñ¾­Á×Ëáø (CaN) ÍŽá £¬ÒÖÖƻTϸ°ûºËÒò×Ó £¨NFAT£©µÄÈ¥Á×ËữʹÆä²»¿É½øÈëºËÄÚ £¬´Ó¶øÒÖÖÆIL-2ºÍ IL-4µÄת¼ £¬´Ó¶ø½µµÍЧӦ TÁÜ°Íϸ°ûµÄ¹¦Ð§ ¡£

? Voclosporine £¨·ü»·æßËØ£©

Voclosporin£¨ÎÖ»·æßËØ£©ÊÇÒ»ÖָƵ÷Éñ¾­Á×ËáøÒÖÖƼÁ ¡£VoclosporinÊÇ»·æß¾úËØA£¨cyclosporine A£©µÄÒ»ÖֽṹÀàËÆÎï ¡£Óë CsA Ïà±ÈÏÔʾ³ö¸üÇ¿µÄ¸Æµ÷Éñ¾­Á×Ëáø (CaN)  ÒÖÖÆ×÷Óú͸üºÃµÄ´úлÎȹÌÐÔ ¡£Óëµ¥¶ÀʹÓÃCsA Ïà±È £¬VoclosporinÌá¸ßÁË»¼ÕßµÄÉúÑÄÂʲ¢Ô¤·ÀÁËÉöË¥½ß £¬VoclosporinÒѱ»FDAÅú×¼ÓÃÓÚÖÎÁÆÔ˶¯ÐÔÀÇ´¯ÉöÑ×(LN) ¡£

4-Cyclophilin-A-ºÍVoclosporine·Ö×Ó½ºµÄ½á¹¹.jpg

Cyclophilin A ºÍVoclosporine·Ö×Ó½ºµÄ½á¹¹[3]

? Rapamycin£¨À×ÅÁùËØ£©

RapamycinÊÇÁíÒ»ÖÖÃâÒßÒÖÖÆÐÔ×ÔÈ»²úÆ· £¬¿ÉÍŽá FKBPs ¡£RapamycinµÄÃâÒßÒÖÖÆ×÷Óò»ÊÇͨ¹ýÒÖÖƸƵ÷Éñ¾­Á×Ëáø (CaN)½éµ¼µÄ ¡£RapamycinÓë FKBPs ¼°mTORÐγÉÈýÔª¸´ºÏÎï ¡£mTOR ¶Ôϸ°ûÉú³¤ºÍÔöÖ³Ïà¹ØµÄÐźÅͨ·¾ßÓÐÖØ´óÓ°Ïì ¡£mTORÊÇϸ°ûÉú³¤ºÍÔöÖ³µÄÖ÷ÒªÒò×Ó £¬ËüµÄ±äÒìÓëÖ×ÁöÇ×½üÏà¹Ø ¡£ÓÉÓÚRapamycin¼°ÆäÑÜÉúÎï½éµ¼·Ç¿ÉÒ©ÐÔ°ÐÂÑ°×mTORÌìÉúFKBP-Rapa-mTORÈýÔª¸´ºÏÎï £¬ÒÔÊÇÆä¾ßÓÐÀàËÆ·Ö×Ó½ºµÄ×÷Óà £¬µ÷ÀímTORµÄ¶àÏЧ ¡£

? FK506£¨Tarcrolimus £»Ëû¿ËĪ˾£©

FK506ÓÃ×÷Æ÷¹ÙÇãÔþµÄ¿Ú·þÒ©Îï»òţƤѢµÄ¾Ö²¿ÓÃÒ© £¬¾ßÓÐÃâÒßÒÖÖÆ×÷Óà £¬FK506Óë¡°FK506 ÍŽáÂѰס±(FKBP)ÍŽá £¬¶ø²»ÊÇÇ×»·ËØ ¡£¶øÆäÖÐÓëFK506ºÍÀ×ÅÁùËØÍŽáµÄFKBP×îÏÈÈ·¶¨µÄÊÇFKBP12 ¡£Óë CsA ¶Ô¸Æµ÷Éñ¾­Á×ËáøµÄ·Ç¾ºÕùÐÔÒÖÖÆÀàËÆ £¬ FK506/ FKBP¸´ºÏÎïͨ¹ýÒÖÖƸƵ÷Éñ¾­Á×ËáøʩչÆäÃâÒßÒÖÖÆ×÷Óà ¡£

5-À×ÅÁùËØ¡¢FK506-ÓÕµ¼µÄ-FKBP-ÂÑ°×ÖÊÏ໥×÷ÓÃ.jpg

À×ÅÁùËØ¡¢FK506 ÓÕµ¼µÄ FKBP-ÂÑ°×ÖÊÏ໥×÷ÓÃ[3]

ÉÏÊöÒ©Îï½éµ¼Á½¸öÂÑ°×µÄÏ໥×÷Óà £¬ÐγɵÄÈýÔª¸´ºÏÎï×è¶ÏÁË°ÐÂѰ׵Ĺ¦Ð§ £¬ÒÔÊÇËüÃDZ»³Æ֮Ϊ·Ö×Ó½º ¡£

? ɳÀû¶È°·£¨Thalidomide£©ºÍÀàËÆÎï (IMiD)

CRBN E3 ÅþÁ¬Ã¸±»°ÐÂÑ°×½µ½â¼Á (TPD) ÕÐļ £¬´Ó¶øÓÕµ¼·ºËØ»¯ºÍËæºóµÄ°ÐÂÑ°×ÂÑ°×øÌå½µ½â ¡£¶øÍŽá E3 ÅþÁ¬Ã¸ CRBN µÄС·Ö×ÓÊÇÑо¿×î¶àµÄ·Ö×Ó½º ¡£É³Àû¶È°·¼°ÆäÑÜÉúÎï £¨IMiD£©Í¨¹ýÎÈ¹Ì CRBN ¶øÊ©Õ¹·Ö×Ó½ºµÄ×÷Óà £¬²¢ÕÐļ¼¸ÖÖе×Îï¾ÙÐзºËØ»¯ £¬µ¼ÖÂת¼Òò×Ó (IKZF1) ºÍ Aiolos (IKZF3) µÄÂÑ°×øÌå½µ½â ¡£IKZF1ºÍIKZF3ÊÇÁÜ°Íϸ°ûÆ×ϵת¼Òò×Ó £¬ÊǶ෢ÐÔ¹ÇËèÁö¶ñÐÔ½¬Ï¸°û´æ»îµÄÒªº¦µ÷ÀíÒò×Ó ¡£IKZF1ºÍIKZF3ÓÉÓÚȱ·¦¿É³ÉÒ©µÄÍŽá¿Ú´ü £¬±»ÒÔΪÊDz»¿É³ÉÒ©µÄ°ÐÂÑ°× ¡£É³Àû¶È°·¼°ÆäÀàËÆÎïÀ´ÄǶȰ·(Lenalidomide)ºÍ²´Âí¶È°·(Pomalidomide)¿ÉÒÔÓÕµ¼CUL4-DDB1-RBX1-CRBN E3ÅþÁ¬Ã¸¸´ºÏÎïµÄÐγÉ ¡£ÕâÖÖÈýÔª¸´ºÏÎïÔö½øIKZF1ºÍIKZF3µÄ·ºËØ»¯ºÍ½µ½â £¬ÒÖÖƶ෢ÐÔ¹ÇËèÁöϸ°ûÔöÖ³µÄºÍBϸ°û·Ö½â ¡£ÕâÈýÖÖÒ©Îï±»ÃÀ¹úFDAÅú×¼ÓÃÓÚÖÎÁƶ෢ÐÔ¹ÇËèÁö ¡£

? CC-885

CC-885×÷ΪÊÇÒ»ÖÖCRBNµ÷Àí¼Á £¬ÔÚ¶àÖÖÖ×Áöϸ°ûÖоßÓп¹ÔöÖ³»îÐÔ ¡£CC-885 ¿ÉÒÔÓÕµ¼ IKZF1 ½µ½â £¬»¹¿ÉÒÔÔö½øCRBNÓëÐÂÐ͵×ÎïGSPT1µÄÍŽá £¬°ÐÏòÆä½µ½â ¡£CC-885 ¶Ô»¼ÕßȪԴµÄ¼±ÐÔËèÐÔ°×Ѫ²¡ (AML) ϸ°ûÏÔʾ³öÑÇÄÉĦ¶ûŨ¶ÈµÄЧÁ¦ ¡£

6-ɳÀû¶È°·ºÍÀàËÆÎï·Ö×Ó½º(IMiD).jpg

ɳÀû¶È°·ºÍÀàËÆÎï·Ö×Ó½º(IMiD)[2]

? (R)-CR8£¨CR8£©

Ç°ÃæµÄ¹æ·¶ÊÇÔÚÒÑÖª¿¹Ö×Áö»îÐԵĻúÖÆÑо¿»ù´¡ÉÏÕ¹ÏÖ³öµÄ·Ö×Ó½º £¬¿ÉνÓÉÎÞÒâ·¢Ã÷µÃÀ´µÄ £¬»¯ºÏÎïCR8ÔòÊÇÓÐÄ¿µÄɸѡ¶ø·¢Ã÷µÄ ¡£SabickiµÈ½«4518¸öÒ©Îï»òÁÙ´²Ç°Ð¡·Ö×ÓÓë578ÖêÖ×Áöϸ°ûηõ £¬²â¶¨ÁË499Öêϸ°ûÖÐE3·ºËØÅþÁ¬Ã¸µÄmRNAˮƽ £¬´Ó¶ø·¢Ã÷ÁËCR8 ¡£CR8×÷Ϊ·Ö×Ó½º £¬ÍŽáÓÚCDK12-cyclin K £¬²¢ÓëE3ÅþÁ¬Ã¸CUL4µÄÏνÓÂÑ°×DDB1Ö®¼äÐγɸ´ºÏÎïDDB1-CR8-CDK12 £¬´Ó¶øʹcyclin K±¬·¢·ºËØ»¯ £¬¼ÌÖ®½«Æä½µ½â¶øɱÉËÖ×Áö ¡£ÔÚ´Ë £¬CR8¼ÓÈëµÄÂÑ°×-ÂÑ°×Ï໥×÷ÓÃÈƹýÁ˶Ե×ÎïÊÜÌåµÄ»¥²¹ÐÔÒªÇó ¡£

7-RBX1--CUL4-DDB1-(CRL4)-ÓëR-CR8-CDK12-cycK¸´ºÏÎïÏàÍŽá.jpg

RBX1- CUL4-DDB1 (CRL4) ÓëR-CR8-CDK12-cycK¸´ºÏÎïÏàÍŽá[4]

? GT919

GT919½ºÄÒÊÇÒ»¿î·Ö×Ó½º½µ½â¼Á £¬Ò²ÊDZêÐÂÉúÎïµÄÊ׸ö·Ö×Ó½º½µ½â¼Á²úÆ· £¬ÒÑ»ñµÃÃÀ¹úʳÎïÒ©Æ·¼àÊÓÖÎÀí¾Ö£¨FDA£©Åú×¼½øÈëÁÙ´²ÊÔÑé £¬ÓÃÓÚ¶ñÐÔѪҺÖ×ÁöµÄÖÎÁÆ ¡£·Ö×Ó½º½µ½â¼ÁÊÇÒ»Àà¿ÉÓÕµ¼E3·ºËØÅþÁ¬Ã¸µ×ÎïÊÜÌåÓë°ÐÂÑ°×Ö®¼äÐÂÐÍÏ໥×÷Óà £¬´Ó¶øµ¼Ö°ÐÂÑ°×½µ½âµÄС·Ö×Ó ¡£¾Ý±êÐÂÉúÎïÐÂΟåÏÈÈÝ £¬GT919ÖÂÁ¦ÓÚ½â¾öÏÖÔÚÁÙ´²ÉÏÀ´ÄǶȰ·ÀàÒ©ÎïµÄÄÍÒ©ÐÔ¼°Çå¾²ÐÔÎÊÌâ ¡£

¹ØÓÚGT919µÄÑз¢ £¬williamÍþÁ®ÑÇÖÞ¹Ù·½ÒÀ¸½ÔúʵµÄÑз¢ÊµÁ¦ £¬¸ßЧÍê³ÉÁËÆä´ÓÒ©Îï·¢Ã÷¹âÁÙ´²É걨 £¬°üÀ¨Ò©Îï·¢Ã÷¡¢Ò©Ñ§Ñо¿¡¢ÁÙ´²Ç°Ñо¿µÈһվʽÁÙ´²Ç°Ñо¿·þÎñ £¬»ñµÃÁ˱êÐÂÉúÎïµÄ¸ß¶ÈÈÏ¿É ¡£ÐÂÒ©»ñÅúÀë²»¿ªÏàÖúË«·½È«Á¦ÒÔ¸°µÄͨÁ¦ÅäºÏ ¡£williamÍþÁ®ÑÇÖÞ¹Ù·½ÔÚÓë±êÐÂÉúÎïµÄÏ໥ÐÅÍС¢Ï໥֧³ÖÏ £¬ÎªGT919ÌṩÁËһվʽÁÙ´²Ç°Ñз¢·þÎñ £¬ÖúÁ¦»ñÅúÁÙ´² £¬Õ¹ÏÖÁËÁ¢ÒìÒ©ÆóµÄÔ­ÑÐÁ¢ÒìʵÁ¦ £¬Ò²ÔÙ´ÎÌåÏÖÁËwilliamÍþÁ®ÑÇÖÞ¹Ù·½Ò»Õ¾Ê½ÉúÎïÒ½Ò©ÁÙ´²Ç°Ñз¢·þÎñƽ̨µÄÄÜÁ¦¼°ÓÅÊÆ ¡£

8-williamÍþÁ®ÑÇÖÞ¹Ù·½×¨·Ã½ª±êԺʿ.jpg

£¨µã»÷Éó²é£ºwilliamÍþÁ®ÑÇÖÞ¹Ù·½×¨·ÃԺʿ£©

×ܽá

ÂÑ°×-ÂÑ°×Ï໥×÷Óà (PPI)¹ØÓÚÐí¶àϸ°ûÀú³ÌÖÁ¹ØÖ÷Òª ¡£ÈôÊDZ¬·¢ÂÑ°×ÖÊÏ໥×÷ÓÃʧµ÷³£³ £»áµ¼Ö¶àÖÖ¼²²¡µÄ±¬·¢ £¬ÈçÖ×ÁöºÍ°¢¶û´Äº£Ä¬²¡µÈ ¡£ÒÔÊÇÔÚÂÑ°×Ï໥×÷ÓÃʧµ÷²¢µ¼Ö¼²²¡±¬·¢Ê± £¬¿ª·¢µ÷ÀíÕâЩÂÑ°×Ï໥×÷ÓõÄÒ©Îï³ÉÁËÁÙ´²´ý½â¾öµÄÄ¿µÄ ¡£ÏÖÔÚ¾ø´ó²¿·ÖÒ©ÎïÊÇÂÑ°×ÒÖÖƼÁ ¡£È»¶øÐí¶àµ¼Ö¼²²¡µÄÂÑ°×ÄÑÓÚ±»¹Å°åС·Ö×ÓÒ©Îï°ÐÏò,ÕâЩÂÑ°×±»³ÆΪ¡°²»¿É³ÉÒ©¡±°Ðµã ¡£¶ø·Ö×Ó½º¿ÉÒÔÕë¶ÔһЩ²»¿É³ÉÒ©µÄ°Ðµã¾ÙÐÐÒ©Î↑·¢ ¡£

·Ö×Ó½º¿ÉÒÔÔöÇ¿ºÍÎȹÌÂÑ°×-ÂÑ°×Ï໥×÷Óà (PPI)¡¢ÐÞ¸´ ÂÑ°×-ÂÑ°×Ï໥×÷Óà (PPI)²¢Ôö½øÐ嵀 ÂÑ°×-ÂÑ°×Ï໥×÷Óà (PPI) ¡£·Ö×Ó½º¿ÉÒÔͨ¹ýÒÖÖÆ»ò¼¤»îÂÑ°×ÅóÙ­»òͨ¹ýÕÐļE3 ·ºËØÅþÁ¬Ã¸°ÐÏòÂѰ׸´ºÏÎï¾ÙÐнµ½â £¬´Ó¶øÀ´µ÷ÀíÂÑ°×¹¦Ð§ ¡£ÒÔºÏÀíµÄ·½·¨Éè¼Æ·Ö×Ó½ºÒ»Ö±ÊDz¢½«¼ÌÐøÊÇÒ»¸öÌôÕ½ ¡£ÏÖÔÚ´ó´ó¶¼·Ö×Ó½º¼°Æä×÷ÓûúÖÆÒ»Ñùƽ³£ÊÇÎÞÒâ·¢Ã÷µÄ ¡£¶ø·Ö×Ó½ºµÄɸѡÉ漰С·Ö×Ó»¯ºÏ¿âµÄ¸ßͨÁ¿É¸Ñ¡ £¬ÕâÏîÊÂÇéÓеãÀàËÆ´óº£ÀÌÕë ¡£Õ¹ÍûδÀ´ £¬Ñо¿ÂÑ°×ÖÊ-ÂÑ°×ÖÊÏ໥×÷Óú͹¦Ð§ÈýÔª½á¹¹¹ØÓÚÒÔ¸ßͨÁ¿·½·¨ºÏÀíµØÉè¼Æ·Ö×Ó½ºÖÁ¹ØÖ÷Òª ¡£ÎÒÃÇÆÚ´ýδÀ´¿ÉÒÔ¸ü¸ßЧµØɸѡÉõÖÁƾ֤µ×Îï½á¹¹¾ÙÐÐÀíÐÔÉè¼ÆȫеķÖ×Ó½º £¬ÓÃÓÚ½µ½âÌåÄÚ´ó×ڵġ°²»¿É³ÉÒ©¡±µÄ¼²²¡°Ðµã ¡£

williamÍþÁ®ÑÇÖÞ¹Ù·½Õë¶Ô°ÐÏòÂÑ°×½µ½âϵÁУ¨ÈçPROTAC ¡¢·Ö×Ó½ºµÈ£©Ò©ÎïÑз¢·þÎñƽ̨°üÀ¨Éè¼ÆºÏ³É ¡¢¾ÙÐÐÌåÍâɸѡ¡¢¾ÙÐж¯ÎïÌåÄÚҩЧ¼ì²âºÍ PK/PD Ñо¿¡¢Ò©Ñ§ÆÊÎö¡¢Ò©Îï´úл¶¯Á¦Ñ§Ñо¿ºÍÇå¾²ÐÔÆÀ¼Û £¬²¢»ã×ÜʵÑéЧ¹ûºÍÖÊÁϾÙÐÐIND É걨 £¬ÒÔÖúÁ¦¿Í»§¼ÓËÙ°ÐÏòÂÑ°×½µ½âϵÁÐÒ©ÎïÒ©ÎïµÄÑз¢Àú³Ì ¡£williamÍþÁ®ÑÇÖÞ¹Ù·½ÒÀÍнü20Äê»ýÀÛÐγɵÄÊÖÒÕÓÅÊƺÍÑз¢Æ½Ì¨ÓÅÊÆ £¬Î§ÈÆÐÂÒ©Ñз¢ÐèÇóÒ»Ö±ÍØÕ¹¹¤ÒµÁ´ÉÏÏÂÓÎÁìÓò £¬ÀֳɴòÔìÁËÈ«·½Î»Ò»Ì廯µÄÁÙ´²Ç°CRO·þÎñģʽ £¬²»µ«¿É½«¹Å°åÑз¢»·½ÚÎÞ·ìÏνӵش®Áª £¬»¹¿ÉÕûºÏ³É²¢ÁªÊ½µÄÑз¢Ä£Ê½ £¬·ºÆð³öÑÏÃÜÍýÏë¡¢¸ßЧЭͬ¡¢ÓÐÐòÍƽøµÄ·þÎñÓÅÊÆ £¬¿É¸ü¶à¡¢¸ü¿ì¡¢¸üºÃ¡¢¸üÊ¡µØ¸³ÄÜÐÂÒ©Ñз¢ ¡£

ÃÀÑÐ|°ÐÏòÂÑ°×½µ½âϵÁлØÊ×

? °ÐÏòÂÑ°×½µ½âϵÁÐ(Ò»)£ºPROTACÊÖÒÕ¿ªÆôÑз¢ÐÂÁìÓò

? °ÐÏòÂÑ°×½µ½âϵÁÐ(¶þ)£ºÈ«Á÷³ÌDMPK·þÎñ¶¦Á¦´ó¾ÙÏàÖúPROTACÒ©ÎïÑз¢

²Î¿¼ÎÄÏ×

[1] Janet M Sasso, et al. Molecular Glues: The Adhesive Connecting Targeted Protein Degradation to the Clinic. Biochemistry. 2023 Feb 7;62(3):601-623. doi: 10.1021/acs.biochem.2c00245.

[2] Evita G. Weagel, et al. Molecular glues: enhanced protein-protein interactions and cell proteome editing. Medicinal Chemistry Research volume 31, pages1068¨C1087 (2022)

[3] Thomas M. Geiger, et al. Clues to molecular glues. Current Research in Chemical Biology. Volume 2, 2022, 100018.

[4] Miko?aj S?abicki, et al. The CDK inhibitor CR8 acts as a molecular glue degrader that depletes cyclin K. Nature. 2020 Sep;585(7824):293-297. doi: 10.1038/s41586-020-2374-x.

[5] Camila Flores, et al. Lessons to Learn From Low-Dose Cyclosporin-A: A New Approach for Unexpected Clinical Applications. Front Immunol. 2019 Mar 28;10:588. doi: 10.3389/fimmu.2019.00588.

[6] Weilin Lin, et al. Conformational Heterogeneity of Cyclosporin A in Cyclophilin 18 Binding. PLoS One. 2016 Apr 15;11(4):e0153669. doi: 10.1371/journal.pone.0153669.

[7] Shanique Alabi. Novel Mechanisms of Molecular Glue-Induced Protein Degradation. Biochemistry. 2021 Aug 10;60(31):2371-2373. doi: 10.1021/acs.biochem.1c00353.

[8] Shiyun Cao, et al. Defining molecular glues with a dual-nanobody cannabidiol sensor.  Nat Commun. 2022 Feb 10;13(1):815. doi: 10.1038/s41467-022-28507-1.

Ïà¹ØÐÂÎÅ
¡Á
ËÑË÷ÑéÖ¤
µã»÷Çл»
ÍøÕ¾µØͼ
ÓÑÇéÁ´½Ó£ºk1ÌåÓý  ¿­Ê±ÍøÕ¾Ê×Ò³  ok138Ì«Ñô¼¯ÍÅ  ATMÓéÀÖ  PPµç×Ó  Î¤µÂ¹ÙÍø  ÐÓöÎƽ̨  ok138Ì«Ñô¼¯ÍÅ  jdbµç×ÓÓÎϷƽ̨  AGÆì½¢Ìü  ok138Ì«Ñô¼¯ÍÅ  ½ðʨ¹ó±ö»á3420055  amjs°Ä½ðɳÃÅ  ×ðÁú¿­Ê±  ¿­Ê±ÍøÕ¾Ê×Ò³